Vladonix

Vladonix is peptide complex A-6, extracted from the thymus of calves under twelve months old at 10 mg per capsule. The claimed effects mirror Thymalin's: improved T-lymphocyte maturation, normalised CD4/CD8 ratio and better lymphocyte proliferative response. The injectable form of this material has a genuine human survival signal behind it from the Khavinson mortality cohort. The capsule does not, and the extra assumption it requires - that a thymic peptide fraction survives digestion and reaches the immune compartment intact - has never been independently verified.

Targets: Thymus, T-lymphocyte maturation, CD4/CD8 ratio

• · 10 mg of peptide complex per capsule. Two a day from a 20-capsule bottle is a ten-day course.

Work out your exact syringe units →

• uncommonMild digestive upset— Often excipient-related.
• uncommonTransient fatigue early in a course— Reported anecdotally; self-limiting.
• rareAllergic reaction to bovine protein— Animal-tissue-derived product.
• rareAutoimmune symptom flare— Mechanistically plausible for an immune-directed preparation.

• Active autoimmune disease - immune stimulation is the stated intent.
• Transplant recipients or anyone on deliberate immunosuppression.
• Known bovine protein allergy.
• Pregnancy and breastfeeding - no data.

• redundantthymalin-cytomax — Same source material, injectable versus oral. Run one.
• redundantthymosin-alpha-1 — Thymosin alpha-1 is a defined synthetic thymic peptide with approvals in over 30 countries - a much stronger option for the same goal.
• conflictimmunosuppressants — Directly opposed pharmacology.

• · CBC with differential before and after a course.
• · Track infection frequency and duration across the following season - that is the outcome that matters.

Sold as a food supplement in Russia and much of Europe; imported elsewhere as a dietary supplement. Not an approved drug.

• Khavinson & Morozov 2003, peptides of pineal gland and thymus prolong human life (injectable form) (trial)
• Khavinson & Malinin, Gerontological Aspects of Genome Peptide Regulation (Karger monograph) (review)

Vladonix has no primary literature of its own - a PubMed search for the brand returns nothing - so the mechanistic content is entirely Thymalin's, and that record is where the detail lives. The one point genuinely worth making here is the dipeptide argument, because it is the only place in the Cytomax line where the oral route has a mechanistically plausible defence. Khavinson's 2023 paper attributes Thymalin's activity to Lys-Glu and Glu-Trp within the complex. Di- and tripeptides are transported intact across the intestinal brush border by PepT1, a real, well-characterised proton-coupled transporter that carries beta-lactam antibiotics and ACE inhibitor prodrugs into the bloodstream every day. If the active moiety of a thymic extract really is a dipeptide, then oral delivery of that moiety is not implausible in the way that oral delivery of a 4 kDa peptide fraction is. What is missing is any evidence that the capsule contains those dipeptides in free form, in an effective quantity, or that plasma levels rise after a dose. The argument is available; the measurement is not.

Two things. First, the evidence transfer: vendors quote the 266-person mortality cohort on a capsule that has never been studied, and buyers reasonably assume the number applies to what they are swallowing. It does not. Second, autoimmunity - this is an immune-directed product and someone with quiescent Hashimoto's, psoriasis or inflammatory bowel disease taking it daily for a month has a mechanistically plausible route to a flare that will not obviously look drug-related when it arrives weeks later. Add the standard bovine-extract sourcing caution and the lactose excipient problem, and the practical advice is: if you want this claim, buy the injection, and if you have autoimmune disease, do not buy either.

• No identified receptor — None published

  No receptor has been identified for this preparation or its injectable parent.

• T-lymphocyte maturation and CD4/CD8 ratio (claimed, inherited from Thymalin)

  The CD117-to-CD28 differentiation result belongs to Thymalin in cell culture. It has never been shown for an orally dosed capsule.

• PepT1 intestinal peptide transporter (hypothetical route) — Not measured for these peptides

  If the active moieties are the dipeptides Lys-Glu and Glu-Trp, PepT1 provides a genuine mechanism for intact intestinal absorption. This is a hypothesis with a real transporter behind it, not a demonstrated pathway.

Nothing acute. Days one to five: some users report transient fatigue early in a course, self-limiting. Weeks three to four: the window in which lymphocyte counts would move if anything is happening, matching the injectable literature. Months three to twelve: infection frequency and severity across a season, which is the outcome this is genuinely sold on and the only one worth judging it by. Keep a log, because nobody remembers last winter accurately.

Vladonix with Thymalin or Vilon is duplication across formats. Vladonix with Endoluten mirrors the Thymalin-plus-Epithalamin pairing from the mortality cohort and is the intended architecture of the capsule line - which is a marketing design rather than a tested protocol. Never combine with immunosuppression: ciclosporin, tacrolimus, methotrexate, biologics or a transplant regimen. Thymosin alpha-1 is the better-evidenced alternative for the same goal, not a partner.

Against injectable Thymalin: the injection has the mortality cohort, the COVID comparative study and the stem-cell differentiation work. The capsule has the same source material and an unmeasured absorption step. Against thymosin alpha-1: a defined 28-residue synthetic with approvals in more than thirty countries and randomised data - by a wide margin the best-evidenced option for thymic immune support. Against Vilon: the synthetic dipeptide, cheap, defined, and if the dipeptide attribution is correct, arguably the same thing as this capsule's active ingredient without the extract. Against zinc, vitamin D repletion and vaccination for immune resilience: all cheaper, all with real data.

$70–$200/month. A 20-capsule bottle is a ten-day course at two a day. Indicative pricing for the branded Russian product, not verified against vendor listings in this session.

• ?No indexed primary literature exists for Vladonix under this name.
• ?Oral bioavailability of the peptide complex has never been measured, though the dipeptide-PepT1 argument gives it more plausibility than the other Cytomax capsules.
• ?Whether the capsule contains free Lys-Glu and Glu-Trp in effective quantity is unknown.
• ?No controlled trial of the capsule format exists for any endpoint.
• ?Autoimmune risk is mechanistically plausible and completely uncharacterised.
• ?Composition is not published lot by lot.
• ?Cost figures are indicative estimates and were not verified against live vendor listings in this session.

• Peptides of pineal gland and thymus prolong human life Khavinson VKh, Morozov VG, Neuro Endocrinology Letters, 2003 · PMID 14523363

  The mortality cohort quoted in Vladonix marketing. The material was injected. The evidence belongs to Thymalin.

• The Influence of KE and EW Dipeptides in the Composition of the Thymalin Drug on Gene Expression and Protein Synthesis Involved in the Pathogenesis of COVID-19 Linkova N, Khavinson V, Diatlova A, et al., International Journal of Molecular Sciences, 2023 · PMID 37686182

  The dipeptide attribution, which is the only argument that gives an oral thymic peptide product a plausible absorption route.

• Thymalin: Activation of Differentiation of Human Hematopoietic Stem Cells Khavinson VK, Linkova NS, Kvetnoy IM, et al., Bulletin of Experimental Biology and Medicine, 2020 · PMID 33237528

  The cellular mechanism, established in vitro for the injectable material.